PubMed Health⌕ Search

Biomedical subjects

F Negro

Publications and source records attributed to F Negro.

At least 73 records · Page 4Linked to original sources
PubMed1997

Intrahepatic expression of c-fos, c-myb and c-myc oncogenes: correlation with virus-induced chronic liver disease and response to interferon.

BACKGROUND & AIMS: Oncogenes were activated in experimental models of hepatocyte regeneration. We studied the intrahepatic expression of c-fos, c-myb and c-myc protooncogenes in 117 patients with chronic liver disease: 12 with hepatitis B, 15 HBsAg carriers, 73 with hepatitis C and 17 with non-viral liver damage. METHODS: Oncoproteins were detected by indirect immunofluorescence using high affinity and monoclonal antibodies. Grade and stage of liver damage were measured by numerical score. RESULTS: Nuclear c-fos and/or c-myb were found in 7 (58.3%) hepatitis B patients, in 38 (52%) hepatitis C patients, in 1 (6.6%) HBsAg carrier (p < 0.004) and in none of the non-viral disease patients (p < 0.0001). In no case was c-myc detected. Oncoproteins were correlated with the histological activity index (p < 0.0001) and its components: lobular degeneration and periportal necrosis (p < 0.0001), fibrosis (p < 0.005) and portal inflammation (p < 0.03). Thirty-one chronic hepatitis C patients were treated with alpha-IFN: 9 out of 14 oncoprotein-positive patients (64%) were non-responders, 5 (36%) relapsed and none was a sustained responder. Conversely 9 out of 17 (53%) oncoprotein-negative patients, including 3 patients with histologically active cirrhosis, showed long-term response (p < 0.005). CONCLUSIONS: Intrahepatic c-fos and c-myb were detected in chronic viral hepatitis patients, but not in non-viral liver diseases. Their expression correlated with the grade and stage of liver disease and with poor response to alpha-IFN.

Adult↗
PubMed1996

Lack of monomeric IgM anti-hepatitis C virus (HCV) core antibodies in patients with chronic HCV infection.

Antibodies of the IgM class against the hepatitis C virus core antigen are found in up to 70% of patients with either acute or chronic hepatitis C. The sedimentation rate of such IgM was analyzed by rate-zonal centrifugation of nine sera taken from seven patients, two acutely and five persistently infected with hepatitis C virus. All patients had circulating high-molecular weight (i.e. pentameric) IgM, indicating that the production of low molecular weight IgM, commonly observed in other persistent viral infections, does not apply to hepatitis C virus and cannot be used to distinguish acute from chronic hepatitis C virus infection.

Chronic Disease↗
PubMed1996

Immunolocalization and gene expression of oxytocin receptors in carcinomas and non-neoplastic tissues of the breast.

Recent evidence indicates that oxytocin (OT), in addition to the induction of myometrial and myoepithelial cell contraction, can influence proliferation and differentiation in developing mammary glands and in breast cancer cells, hence the interest in detecting and locating OT receptors (OTRs). We produced rabbit antisera and a monoclonal antibody against a synthetic peptide corresponding to the carboxy terminus of the predicted OTR sequence. We tested their specificity in immunoblasts and immunocytochemical tests. All of the antibodies specifically stained myometrium (at term of pregnancy). In the human breast, OTRs were detected in myoepithelial cells along ducts of normal lobules and in sclerosing adenosis. Intraductal cells in benign hyperplastic lesions were also positive. OTRs were demonstrated in cases of primary and metastatic carcinomas of the breast. In the same tissues, OTR gene expression was shown by reverse transcriptase polymerase chain reaction procedures detecting the specific mRNA. These results suggest that the interaction between OT and its receptors might play a role in the origin and evolution of non-neoplastic lesions and carcinomas of the breast.

Amino Acid Sequence↗
PubMed1996

In situ detection of hepatitis C virus--a critical appraisal.

Hepatitis C virus (HCV) is a single-stranded RNA virus that replicates at a low level. Accordingly, the detection of HCV RNA requires molecular techniques such as reverse transcription polymerase chain reaction and branched chain DNA signal amplification assay. Although very sensitive, these assays do not allow specific localization of HCV within the liver. In situ detection of HCV genome and gene products is important to allow for the identification of cellular tropism, obtaining clues to the subcellular site of viral replication, and defining host-viral interactions. In situ hybridization, in situ reverse transcription polymerase chain reaction and immunohistochemistry have been applied for the localization of HCV genome and gene products. However, all these techniques were found to have their limitations and conflicting results have been reported based on all three techniques. This review will critically discuss the available data with an attempt to assist researchers to further understand the potential limitations and possible ways to solve these problems. The development of better protocols for the detection and localization of HCV will help to provide a better understanding of the pathobiology of HCV which, in turn, will assist in the design of better therapeutic strategies.

Hepacivirus↗
PubMed1995

Detection of hepatitis D virus RNA in serum by a reverse transcription, polymerase chain reaction-based assay.

We designed a reverse transcription, polymerase chain reaction-based assay for serum hepatitis D virus RNA. Amplified hepatitis D virus cDNA was revealed by ethidium bromide staining, followed by blotting onto a nylon membrane and hybridization with a 32phosphorus-labelled oligonucleotide, or by a DNA enzyme immunoassay (DEIA) using a double stranded DNA-specific monoclonal antibody. The absolute sensitivity was expressed as number of hepatitis D virus RNA molecules, using a serum of known viral RNA concentration. Three sets of primers were used, encompassing the base positions 66-686 (variable rod-stabilizing region), 701-962 (conserved, viroid-like domain) and 886-1,333 (portion of the open reading frame 5 encoding for the carboxyterminus of the hepatitis D antigen) of the viral genome. The lower detection limits, after amplification of the three RNA portions, as assessed by ethidium bromide staining, were 7.5 x 10(6), 7.5 x 10(4) and 7.5 x 10(2) molecules of hepatitis D virus RNA per assay, respectively. The region encompassing bases 886-1,333 was chosen for blotting and hybridization to a radiolabelled oligonucleotide probe or for a capture-based DNA enzyme immunoassay, where the microplate was coated with this same probe. The two procedures showed comparable sensitivity, i.e., about 10 molecules of viral RNA per assay. The specificity of the assay was further on a panel of both anti-hepatitis D-positive and -negative sera. Amplification of serum hepatitis D virus RNA by reverse transcription/polymerase chain reaction followed by detection of the amplified cDNA by DNA enzyme immunoassay is a promising and feasible routine assay for detecting low amounts of circulating virions.

Animals↗
PubMed1995

The fluctuations of hepatitis C virus RNA and IgM anti-HCV (core) serum levels correlate with those of alanine aminotransferases during the hepatitis relapses of patients treated with interferon.

Variations in the serum levels of hepatitis C virus (HCV) RNA. IgM antibody against the HCV 'core' structural protein (c22) and alanine amino-transferase (ALT) were measured in 23 patients with chronic hepatitis C who underwent therapy with interferon-alpha 2a (IFN alpha 2a). Low pretreatment levels of viraemia and undetectable IgM anti-core were significantly associated with a long-term response to treatment. In patients with hepatitis relapses after the end of treatment, HCV RNA levels increased before or at the same time as ALT in 29 out of 34 cases (85%). ALT flares occurred before or simultaneously with IgM anti-core elevations in 18 out of 20 cases (90%). Therefore, post-treatment hepatitis C exacerbations show the same sequence of events seen as in hepatitis B exacerbations (increases of viraemia followed by those of ALT and IgM anti-'core'). These findings underscore the diagnostic and prognostic usefulness of monitoring anti-HCV-positive patients with quantitative assays for HCV markers.

Alanine Transaminase↗
PubMed1995

Diagnosis of hepatitis delta virus infection.

The hepatitis delta virus (HDV) is a cause of severe liver disease in man. Several assays are available to detect both the HDV genome and its only encoded antigen, HDAg, as well as specific antibodies against HDAg (anti-HD), of both the IgG and IgM class. Different serologic patterns enable the clinician to formulate a correct diagnosis, crucial for effective treatment.

Animals↗
PubMed1994

Oxytocin inhibits proliferation of human breast cancer cell lines.

In this study we show that treatment of MDA-MB231 hormone-independent human breast cancer cells with oxytocin (OT) or with the OT analogue F314 induces significant growth inhibition together with a change in cell phenotype. In MCF7 and T47D human breast cancer cells, OT inhibits oestrogen-induced cell growth. In these same cells, OT administration significantly enhances the inhibitory effect of tamoxifen on cell proliferation. MDA-MB231, MCF7 and T47D cells all express mRNA specific for the OT receptor. These data suggest that it may be possible to inhibit breast cancer growth using OT and OT analogues.

Breast Neoplasms↗
PubMed1994

Detection of hepatitis C virus RNA by in situ hybridization: a critical appraisal.

Despite the several papers that have appeared in the literature or have been communicated at scientific meetings, the detection of hepatitis C virus RNA by in situ hybridization seems a difficult goal to achieve. There have been conflicting reports on the type and proportion of hepatitis C virus-infected cells, the intracellular distribution of viral RNA and the topographical association with cell damage. As a consequence, some of the findings should probably be considered as non-specific and all protocols and data critically reviewed before a firm conclusion be made.

Animals↗
PubMed1994

Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2a.

BACKGROUND/AIMS: Prolonged interferon administration to patients with chronic hepatitis C, although increasing the sustained response rate, is poorly accepted and may favor drug resistance. A pulse-treatment schedule would be preferred for compliance and costs. METHODS: One hundred thirty-five patients with chronic hepatitis C received 6 MU units of interferon alfa-2a, three times weekly, continuously for 9 months (group 1: 66 patients) or for two 3-month cycles, separated by 6 months pause (group 2: 69 patients). RESULTS: At the end of therapy, 25 of 54 patients of group 1 (46.3%) and 28 of 60 of group 2 (46.7%) had normal serum aminotransferase levels. Six months after the end of treatment, sustained responders were still similar in the two groups (11 or 16.7% vs. 7 or 10.1%; NS). A loss of response before the end of therapy was seen in 10 patients of group 1 and 6 of group 2; interferon-neutralizing antibodies developed in 1 of 7 and 6 of 6 of such patients, respectively. CONCLUSIONS: The intermittent administration of interferon alfa-2a to patients with chronic hepatitis C shows a sustained response rate comparable with that achieved with continuous treatment at the same dosage. Hepatitis breakthroughs during pulse therapy appeared to be limited to interferon neutralizing antibodies, whereas a prolonged, continuous treatment is more likely to induce other forms of interferon resistance.

Adolescent↗
PubMed1994

Detection of hepatitis C virus RNA by reverse-transcriptase and polymerase chain reaction: clinical applications of quantitative analysis.

Polymerase chain reaction (PCR) applications to diagnostics allowed the detection of viral nucleic acids in expected and unexpected clinical circumstances. This has raised some scepticism on the practical usefulness of PCR in the routine laboratory and emphasized the need for quantitative analysis. We addressed this question detecting HCV-RNA by a single step RT-PCR in serum samples from 50 patients with chronic non-A, non-B hepatitis included in clinical trials for recombinant alpha-interferon therapy. We obtained at least 5 serum specimens from each patient (baseline, during and after therapy samples) during an 18-month mean follow-up (range 12-45 months). RT-PCR was performed on total RNA extracted from 100 microl serum aliquots using primers for the highly conserved 5'NCR of HCV-RNA and 35 amplification cycles. PCR products were analyzed by agarose gel electrophoresis and Southern blot hybridization against a P(32)-oligonucleotide probe. Sensitivity was evaluated in separate experiments on tenfold dilutions of a reference Chimp serum containing 10(6) CID(50)/ml. The overall sensitivity of our assay ranged between 10(2) and 10(3) genome Eq./ml. We establish a semiquantitative score system to evaluate viremia levels: 2 = HCV-RNA levels >10(4) genome Eq./ml; 1 = levels between 10(3) and 10(4) g.Eq./ml; 0 = levels less than 10(2) g.Eq/ml. The reproducibility of this scoring system was confirmed testing repeatedly in duplicate end-point dilutions of positive serum samples. A statistically significant relation was observed between elevated HCV-RNA and ALT values (83.8%, chi-square 159.963 P < 0.001). Response to IFN therapy was significantly better in patients with lower baseline HCV-RNA levels. A time relation was found between flare-ups of serum HCV-RNA levels and ALT elevations higher than 3 x normal values viremia elevations coincident or occurring about 1 month earlier than ALT elevations. This finding suggests that immuno pathogenesis might be responsible of HCV-induced liver damage as in chronic hepatitis B where identical relations were observed between viremia and ALT serum levels. In conclusion, single-step HCV-RNA RT-PCR can be a specific and reproducible semiquantitative assay and provides useful diagnostic informations for therapeutic decision making and monitoring of HCV-infected patients.

Journal Article↗
PubMed1994

Hepatitis type C after orthotopic liver transplantation: reinfection and disease recurrence.

We determined the prevalence of hepatitis C virus markers and the clinical course in patients transplanted for terminal type C or non-A, non-B cirrhosis. Hepatitis C virus infection recurred in 16 of 17 patients (94%) with type C cirrhosis (seropositive for hepatitis C virus prior to surgery) and in 10 of 11 patients (91%) with non-A, non-B cirrhosis whose hepatitis C virus status prior to surgery had not been determined. Markers of hepatitis C virus were detected in 4 of 16 liver transplants whose donors tested negative for hepatitis C virus prior to surgery; this figure represents the risk of hepatitis C virus acquisition from external sources at or after transplantation. In 18 of 26 reinfected patients aminotransferases increased after grafting and remained elevated throughout the 14 to 79 (mean 46.5) months of follow up. The histological findings varied from mild or moderate hepatitis in 15 patients to severe active hepatitis in two patients. Two patients developed cirrhosis; one of them died of intercurrent infection while she was receiving immunosuppressive therapy for chronic rejection. Patients transplanted for hepatitis C virus or non-A, non-B liver disease are at high risk of hepatitis C virus reinfection. However the course of recurrent hepatitis C is most often mild and compatible with a normal life and an excellent survival rate.

Adult↗